Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

NCT03957915 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia Recurrent
Acute Lymphoblastic Leukemia, in Relapse
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukaemia Recurrent
Mixed Phenotype Acute Leukemia

Interventions

DRUG: INA03 administration

Sponsor

Institut Paoli-Calmettes

Collaborators

[object Object]